Retatrutide
Also sold as LY3437943.
- Half-life
- 144 h
- Steady state
- ~30 d
- Class
- Triple agonist
- Category
- GLP-1
Published population averages. Steady state is the usual five half-life rule of thumb, not a measurement. See peptide half-life, explained.
Overview
Retatrutide (LY3437943) is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data showed unprecedented weight loss results of up to 24% body weight reduction. It represents the next evolution beyond dual agonists like tirzepatide.
How it works
Simultaneously activates GLP-1 (appetite suppression, insulin secretion), GIP (enhanced insulin and lipid handling), and glucagon receptors (increased energy expenditure, hepatic fat oxidation, thermogenesis). The glucagon component adds metabolic rate increase absent in GLP-1-only or GLP-1/GIP agents.
Half-life and peak
Terminal half-life is approximately 6 days (~144 hours), supporting once-weekly dosing. Peak plasma levels occur approximately 24–72 hours after subcutaneous injection.
What it is studied for
Phase 2 dose-ranging in obesity and T2DM, triple-agonist metabolic effects, liver fat reduction (MASLD), comparison with dual-agonist approaches.
Research status
Investigational — Phase 3 trials ongoing. Phase 2 results (2023) showed up to 24.2% weight loss at 48 weeks. Not yet approved by any regulatory body.
Sources
- Retatrutide Phase 2 obesity trial — NEJM · doi.org
- ClinicalTrials.gov — Retatrutide studies · clinicaltrials.gov
- Retatrutide PK/PD Phase 1 — Diabetes Care · doi.org
Educational reference only. This page describes what is published about a compound; it is not medical advice, not a recommendation to take anything, and not a dosing guide. Several compounds in this catalog are investigational and are not approved medicines. Talk to a doctor.